Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

被引：4
|
作者：
Marin, Ellen [1 ]
Scott, Sara [2 ]
Maples, Kathryn [3 ]
Joseph, Nisha S. [4 ]
Hofmeister, Craig C. [5 ]
Gupta, Vikas A. [5 ]
Dhodapkar, Madhav V. [5 ]
Kaufman, Jonathan L. [5 ]
Lonial, Sagar [6 ]
Nooka, Ajay K. [2 ]
机构：
[1] Emory Univ Hosp, Winship Canc Inst, Decatur, GA USA
[2] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[3] Pfizer, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189878
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
    Scott, Sara A.
    Marin, Ellen M.
    Maples, Kathryn T.
    Joseph, Nisha S.
    Hofmeister, Craig C.
    Gupta, Vikas A.
    Dhodapkar, Madhav V.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
    Sara A. Scott
    Ellen M. Marin
    Kathryn T. Maples
    Nisha S. Joseph
    Craig C. Hofmeister
    Vikas A. Gupta
    Madhav V. Dhodapkar
    Jonathan L. Kaufman
    Sagar Lonial
    Ajay K. Nooka
    Blood Cancer Journal, 13
  • [3] Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Hodin, Caroline
    Stephenson, Tara
    Trancucci, Danielle
    Perales-Puchalt, Alfredo
    Kobos, Rachel
    Banerjee, Arnob
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing
    Korst, Charlotte L. B. M.
    Groen, Kaz
    Bosman, Patricia W. C.
    van der Valk, Fleur
    Verkleij, Christie P. M.
    Kruyswijk, Sandy
    de Ruijter, Maaike E. M.
    Heijink, Dianne M.
    Kuipers, Maria T.
    Zweegman, Sonja
    van de Donk, Niels W. C. J.
    HEMASPHERE, 2024, 8 (07):
  • [5] Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Matous, Jeffrey V.
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S549
  • [6] Tocilizumab Management in the Cytokine Release Syndrome
    Martin Benito, Cristina
    Sanguesa Dominguez, Silvia
    Gonzalez Rodriguez, Maria Cristina
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 746 - 746
  • [7] Update on Pediatric Cytokine Release Syndrome (CRS)
    Pao, Maryland
    PSYCHO-ONCOLOGY, 2023, 32 : 25 - 25
  • [8] A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)
    Choudhry, Jessica
    Parson, Mandy
    Wright, Jacqueline
    BLOOD, 2018, 132
  • [9] Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
    Liu, Danfei
    Zhang, Tongyue
    Wang, Yijun
    Xia, Limin
    FRONTIERS IN MEDICINE, 2020, 7
  • [10] Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Matous, Jeffrey V.
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345